Engineered exosomes for treatment of metabolic disorders

Abstract

Disclosed is an engineered exosome, comprising (a) an FGF21 polypeptide, fused to a first anchoring polypeptide, (b) an IL-27 polypeptide, fused to a second anchoring polypeptide, and (c) an activin receptor type II polypeptide, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the FGF21 polypeptide, the IL-27 polypeptide and the activin receptor type II polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome in treating metabolic disorders.

Images